MF,PMF,PPV-MF,PET-MF Clinical Trial
Official title:
An Open, Positive Drug-controlled, Parallel-group, Multicenter Phase II Clinical Trial of the Efficacy, Safety, and Pharmacokinetics of Flunotinib Maleate Tablets in the Treatment of Patients With Intermediate- and High-risk Myelofibrosis
This trial adopts a multicenter, open-label, positive drug parallel control clinical trial design, planning to enroll approximately 75 MF participants. Eligible participants will be stratified and assigned in a 1:1:1 ratio to the low-dose fruquintinib maleate tablet group, high-dose fruquintinib maleate tablet group, or the ruxolitinib tablet group. Stratification factors include the Dynamic International Prognostic Scoring System (DIPSS) risk classification (intermediate-2 and high risk)
n/a